Anika Therapeutics (ANIK) said Friday it completed the all-cash sale of its Parcus Medical business to Medacta.
Financial terms were not disclosed.
Anika President and Chief Executive Cheryl R. Blanchard said the sale allows the company to focus on its core hyaluronic acid technology.
Anika said it has agreed to work with Medacta post-sale to ease the transition for employees, distributors, medical customers, and patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.